Treatment with once-weekly semaglutide 7.2 mg conferred a 20.7% weight reduction vs. a 17.5% weight loss with semaglutide 2.4 mg. The safety profile of semaglutide 7.2 mg is similar to other GLP-1s.
Novo Nordisk's STEP UP trial shows semaglutide 7.2 mg delivers superior weight loss and safety compared to lower doses and ...
When applying the treatment policy estimand2, people treated with semaglutide 7.2 mg achieved a superior weight loss of 18.7% compared to a reduction of 15.6% with semaglutide 2.4 mg and 3.9% with ...
Veru's enobosarm showed significant body composition benefits in Phase 2b trials with semaglutide. Extension study results are due in April 2025.
When applying the treatment policy estimand 2, people treated with semaglutide 7.2 mg achieved a superior weight loss of 18.7% compared to a reduction of 15.6% with semaglutide 2.4 mg and 3.9% ...
Clinical trials, including those presented at the 61st European Renal Association Congress, highlight a 24% reduction ... sugar regulation, semaglutide also supports weight management, which ...